Barclays
DYN icon

Barclays’s Dyne Therapeutics DYN Stock Holding History

Barclays’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.48M Buy
215,979
+178,799
+481% +$4.11M ﹤0.01% 2245
2026
Q2 		$826K Buy
37,180
+611
+2% +$11.4K ﹤0.01% 2909
2026
Q1 		$663K Sell
36,569
-412,089
-92% -$7.11M ﹤0.01% 3011
2025
Q4 		$8.78M Sell
448,658
-32,043
-7% -$607K ﹤0.01% 1776
2025
Q3 		$6.08M Buy
480,701
+160,211
+50% +$1.83M ﹤0.01% 2047
2025
Q2 		$3.05M Buy
320,490
+89,266
+39% +$983K ﹤0.01% 2528
2025
Q1 		$2.42M Buy
231,224
+38,985
+20% +$558K ﹤0.01% 2486
2024
Q4 		$4.53M Sell
192,239
-15,070
-7% -$446K ﹤0.01% 2249
2024
Q3 		$7.45M Buy
207,309
+128,246
+162% +$5.1M ﹤0.01% 1708
2024
Q2 		$2.79M Sell
79,063
-4,909
-6% -$143K ﹤0.01% 1904
2024
Q1 		$2.38M Sell
83,972
-69,379
-45% -$1.57M ﹤0.01% 2426
2023
Q4 		$2.04M Buy
153,351
+53,777
+54% +$525K ﹤0.01% 2908
2023
Q3 		$892K Buy
99,574
+17,603
+21% +$190K ﹤0.01% 2412
2023
Q2 		$922K Buy
81,971
+49,883
+155% +$588K ﹤0.01% 2364
2023
Q1 		$370K Buy
32,088
+7,845
+32% +$102K ﹤0.01% 3470
2022
Q4 		$281K Buy
24,243
+7,164
+42% +$82.9K ﹤0.01% 3666
2022
Q3 		$217K Sell
17,079
-62,420
-79% -$716K ﹤0.01% 3149
2022
Q2 		$547K Buy
79,499
+60,313
+314% +$415K ﹤0.01% 2793
2022
Q1 		$185K Buy
+19,186
New +$163K ﹤0.01% 3467

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Barclays's DYN Position: Q3 2026 in Review

Barclays increased its Dyne Therapeutics (DYN) stake by 481% in Q3 2026, buying an estimated $4.11M and bringing the position to 215,979 shares worth $3.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2245.

Barclays first reported a position in DYN in Q1 2022 and has held it in 19 quarters since. The position peaked at $8.78M in Q4 2025. 109 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • Barclays held 215,979 shares of Dyne Therapeutics worth $3.48M as of Q3 2026.
  • Barclays bought 178,799 Dyne Therapeutics shares in Q3 2026, an estimated $4.11M.
  • Dyne Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2245 holding.
  • Barclays first reported a position in Dyne Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Dyne Therapeutics position peaked at $8.78M in Q4 2025.
  • 109 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.